| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/19/2001 | US6248327 Using antibody |
| 06/19/2001 | US6248326 Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor |
| 06/19/2001 | US6248322 Attenuated vaccine for Blastomyces dermatitidis |
| 06/19/2001 | CA2172187C Method of incorporating drugs into a polymer component of stents |
| 06/19/2001 | CA2038577C Utilization and delivery of enzymes |
| 06/19/2001 | CA2022539C Albumin derivatives with therapeutic functions |
| 06/19/2001 | CA2008856C Tocols as adjuvant in vaccine |
| 06/19/2001 | CA2003307C Streptolysin o antigen derivative, its production and uses |
| 06/19/2001 | CA1341255C Therapeutic compositions against sterptococcal infections, transformed hosts, methods of immunization and genetically engineered products |
| 06/14/2001 | WO2001042472A2 DNA ENCODING A NOVEL PROST-Ets POLYPEPTIDE |
| 06/14/2001 | WO2001042471A2 Polypeptides and polynucleotides encoding same |
| 06/14/2001 | WO2001042465A2 Chordin-like molecules and uses thereof |
| 06/14/2001 | WO2001042460A1 Polynucleotides, polypeptides, remedies for cancer and vaccines |
| 06/14/2001 | WO2001042449A2 Methods for introducing genes into mammalian subjects |
| 06/14/2001 | WO2001042445A2 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS |
| 06/14/2001 | WO2001042444A2 Methods for expression of genes in primates |
| 06/14/2001 | WO2001042439A1 Molecular display on multimeric protein scaffolds derived from the e2 component of the alpha-ketoacid dehydrogenase |
| 06/14/2001 | WO2001042438A2 Leukolysin/mmp25/mt6-mmp |
| 06/14/2001 | WO2001042429A1 Infection of eukaryotic cells with viruses in vitro |
| 06/14/2001 | WO2001042423A2 Compositions and methods for detecting stress-inducible proteins |
| 06/14/2001 | WO2001042306A2 Chimeric peptides (short b-cell epitope joined to a t-cell epitope) and their use for immunization |
| 06/14/2001 | WO2001042304A1 Interleukin-1 receptor antagonist-related molecules and uses thereof |
| 06/14/2001 | WO2001042301A1 Interferon-alpha induced gene |
| 06/14/2001 | WO2001042299A2 Hepatitis virus sentinel virus i (svi) |
| 06/14/2001 | WO2001042298A1 Multimeric forms of tnf superfamily ligands |
| 06/14/2001 | WO2001042297A2 Clasp-3 transmembrane protein |
| 06/14/2001 | WO2001042296A2 Clasp-5 transmembrane protein |
| 06/14/2001 | WO2001042295A2 Clasp-7 transmembrane protein |
| 06/14/2001 | WO2001042270A1 Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions |
| 06/14/2001 | WO2001042267A1 Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions |
| 06/14/2001 | WO2001042193A1 β2-ADRENERGIC RECEPTOR AGONISTS |
| 06/14/2001 | WO2001041810A2 Nucleic acid delivery system |
| 06/14/2001 | WO2001041809A1 Application of polyacrylamide gel for forming a capsule in the tissue of a mammal organism, method for cultivating cells and method for therapy of oncological diseases and the diabetes mellitus |
| 06/14/2001 | WO2001041803A1 COMBINATION OF COMPOUNDS THAT INHIBIT THE BIOLOGICAL EFFECTS OF TNF-α AND CD95L IN A MEDICAMENT |
| 06/14/2001 | WO2001041802A1 Vaccine adjuvants comprising ginseng plant extract and added aluminium salt |
| 06/14/2001 | WO2001041800A2 Compositions and methods for stabilizing biological molecules upon lyophilization |
| 06/14/2001 | WO2001041799A1 Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions |
| 06/14/2001 | WO2001041798A1 Induction of immunoglobulin class switching by inactivated viral vaccine |
| 06/14/2001 | WO2001041797A2 Systemic immune response induced by mucosal administration of l ipid-tailed polypeptides without adjuvant |
| 06/14/2001 | WO2001041792A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | WO2001041788A1 INDUCING CELLULAR IMMUNE RESPONSES TO p53 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS |
| 06/14/2001 | WO2001041787A1 INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS |
| 06/14/2001 | WO2001041784A1 Methods and compositions for use in the treatment of filovirus mediated disease conditions |
| 06/14/2001 | WO2001041741A1 Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| 06/14/2001 | WO2001041703A2 Method for treating allergic diseases |
| 06/14/2001 | WO2001009337A3 Moraxella catarrhalis antigens basb122 and basb124 |
| 06/14/2001 | WO2001009189A3 Compositions and methods for the treatment of tumors |
| 06/14/2001 | WO2001003720A3 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 06/14/2001 | WO2001000829A8 Human endogenous retrovirus in breast cancer |
| 06/14/2001 | WO2000035950A9 Reagents and methods useful for detecting diseases of the breast |
| 06/14/2001 | WO1998033528A9 Induction of b cell tolerance |
| 06/14/2001 | US20010003753 Methods for treatment of inflammatory diseases |
| 06/14/2001 | CA2395417A1 Interleukin-1 receptor antagonist-related molecules and uses thereof |
| 06/14/2001 | CA2394917A1 Polypeptides and polynucleotides encoding same |
| 06/14/2001 | CA2394303A1 Interferon-alpha induced gene |
| 06/14/2001 | CA2393960A1 Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions |
| 06/14/2001 | CA2393779A1 Combination of compounds that inhibit the biological effects of tnf-.alpha. and cd95l in a medicament |
| 06/14/2001 | CA2393763A1 Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies |
| 06/14/2001 | CA2393738A1 Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions |
| 06/14/2001 | CA2393730A1 Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| 06/14/2001 | CA2393662A1 Inducing cellular immune responses to p53 using peptide and nucleic acid compositions |
| 06/14/2001 | CA2393659A1 Multimeric forms of tnf superfamily ligands |
| 06/14/2001 | CA2393644A1 Hepatitis virus sentinel virus i (svi) |
| 06/14/2001 | CA2393589A1 Compositions and methods for detecting stress-inducible proteins |
| 06/14/2001 | CA2393532A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | CA2393526A1 Nucleic acid delivery system |
| 06/14/2001 | CA2393454A1 Infection of eukaryotic cells with viruses in vitro |
| 06/14/2001 | CA2393339A1 Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions |
| 06/14/2001 | CA2392764A1 Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions |
| 06/14/2001 | CA2392299A1 Methods for expression of genes in primates |
| 06/14/2001 | CA2390747A1 Systemic immune response induced by mucosal administration of lipid-tailed polypeptides without adjuvant |
| 06/14/2001 | CA2383001A1 Methods for introducing genes into mammalian subjects |
| 06/14/2001 | CA2362685A1 Use of recombinant parainfluenza viruses (pivs) as vectors to protect against infection and disease caused by piv and other human pathogens |
| 06/14/2001 | CA2361563A1 Use of polyacrylamide gel for forming a connective-tissue capsule in a mammal for cultivating allogenic or xenogenic cells |
| 06/13/2001 | EP1106690A2 Polynucleotide encoding autoantigens associated with endometriosis |
| 06/13/2001 | EP1106625A1 Rhesus D specific peptide sequences |
| 06/13/2001 | EP1106183A2 Antibodies to erbB2 and their therapeutic uses |
| 06/13/2001 | EP1105538A2 HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS |
| 06/13/2001 | EP1105528A1 A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| 06/13/2001 | EP1105512A1 Intracellular delivery vehicles |
| 06/13/2001 | EP1105505A2 Compound and method for the prevention and/or the treatment of allergy |
| 06/13/2001 | EP1105503A2 ISOLATED AND PURIFIED HUMAN SOLUBLE GUANYLYLCYCLASE ALPHA1/BETA1 (hsGCALPHA1/BETA1) |
| 06/13/2001 | EP1105501A2 Tpl-2/cot kinase and methods of use |
| 06/13/2001 | EP1105497A1 Cold-adapted equine influenza viruses |
| 06/13/2001 | EP1105496A1 Modified hcv peptide vaccines |
| 06/13/2001 | EP1105495A2 Method for producing yeast expressed hpv types 6 and 16 capsid proteins |
| 06/13/2001 | EP1105493A1 Basb024 outer membrane protein of neisseria meningitidis |
| 06/13/2001 | EP1105492A1 Cloning of basb023 antigen from moraxella catarrhalis |
| 06/13/2001 | EP1105490A1 Nucleic acid molecules encoding inclusion membrane protein c of chlamydia |
| 06/13/2001 | EP1105489A1 Nucleic acid molecules encoding pomp91a protein of chlamydia |
| 06/13/2001 | EP1105488A2 $i(CHLAMYDIA) ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF |
| 06/13/2001 | EP1105487A1 Recombinant multivalent malarial vaccine against plasmodium falciparum |
| 06/13/2001 | EP1105484A1 Antithrombin nucleotides and proteins from horn fly |
| 06/13/2001 | EP1105483A1 Genes involved in the molecular paths for tumour suppression and /or resistance to viruses |
| 06/13/2001 | EP1105477A1 Dcr5, a bmp-binding protein, and applications thereof |
| 06/13/2001 | EP1105466A1 Process for purifying human papillomavirus virus-like particles |
| 06/13/2001 | EP1105427A2 Generation of modified molecules with increased serum half-lives |
| 06/13/2001 | EP1105417A1 Nucleic acid and polypeptide p10 of a borna disease virus (bdv) and their use for diagnostic and immunization purposes |
| 06/13/2001 | EP1105414A2 Synthetic peptides and methods of use for autoimmune disease therapies |
| 06/13/2001 | EP1105411A1 nrdE |